REDWOOD CITY, Calif.,
Oct. 26, 2016 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) today announced
publication in Reviews in Urology of a comprehensive
economic analysis of the use of the Oncotype DX® Genomic
Prostate ScoreTM (GPS) in low-risk prostate cancer
patients. Results showed that use of the GPS results in a net
savings of $2,286 per patient –
including the cost of the test – by decreasing unnecessary
immediate invasive treatment.
"Not all low-risk prostate cancers are aggressive, but it is
critical to know exactly which patient can forego immediate surgery
safely," said study principal investigator David M. Albala, M.D., chief of urology, Crouse
Hospital, Syracuse, New York.
"Better treatment decisions can be made when patients
have genomic information about their prostate tumors. Our
study reconfirms that the GPS provides physicians and patients with
additional risk assessment that resolves uncertainty in prognosis
and informs individuals' treatment decisions based on tumor
biology."
Led by Associated Medical Professionals (AMP) of New York, the study demonstrated that
incorporation of the GPS as part of the treatment decision
algorithm for prostate cancer patients with NCCN very low and
low-risk disease (64 percent of the study population) led to a 21
percent net increase in the use of active surveillance. The study
specifically included prostate cancer patients covered by Excellus
BlueCross BlueShield insurance in New
York. Of these, treatment patterns and cost for 80 men
tested with Oncotype DX were compared to 100 patients in the same
practice without genomic testing.
Based on a real-world practice setting with a contemporary
patient population and using current treatment cost averages, these
published results demonstrated that the use of Oncotype DX
represented a more than 50 percent return on investment over six
months by reducing the cost of unnecessary immediate interventions.
Additional savings can also be expected by removing the cost of
management of associated side effects of treatment such as
impotence and incontinence.
"The cost of caring for prostate cancer patients in the United States is estimated to be
approximately $18 billion by 2020,"
said Phil Febbo, M.D., chief medical
officer, Genomic Health. "The study provides additional
important evidence to support broader adoption of Oncotype DX as we
continue to fulfill Genomic Health's vision to bring precision
medicine to cancer patients, to empower physicians with actionable
molecular information and to provide value and cost savings to our
healthcare systems."
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer tests
applies advanced genomic science to reveal the unique biology of a
tumor in order to optimize cancer treatment decisions. The Oncotype
DX prostate cancer test identifies which clinically low-risk
patients are eligible for active surveillance, as well as those who
may benefit from immediate treatment by predicting disease
aggressiveness. With more than 600,000 patients tested in more than
90 countries, Oncotype DX testing has redefined personalized
medicine by making genomics a critical part of cancer diagnosis and
treatment. To learn more about the Oncotype DX prostate cancer
test, visit www.OncotypeDX.com or
www.MyProstateCancerTreatment.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care by addressing the
overtreatment of the disease, one of the greatest issues in
healthcare today. With its Oncotype IQ™ Genomic Intelligence
Platform, the company is applying its world-class scientific and
commercial expertise and infrastructure to lead the translation of
clinical and genomic big data into actionable results for
treatment planning throughout the cancer patient journey, from
diagnosis to treatment selection and monitoring. The Oncotype
IQ portfolio of genomic tests and services currently consists of
the company's flagship line of Oncotype DX gene expression tests
that have been used to guide treatment decisions for more than
600,000 cancer patients worldwide. Genomic Health is
expanding its test portfolio to include additional liquid- and
tissue-based tests, including the recently launched Oncotype SEQ™
Liquid Select assay. The company is based in Redwood
City, California, with international headquarters
in Geneva, Switzerland. For more information, please
visit, www.GenomicHealth.com and follow the company on
Twitter:
@GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: our business model; the applicability of clinical
and health economic study results to actual outcomes; our ability
to develop and commercialize new tests and expand into new markets
domestically and internationally; and the other risks and
uncertainties set forth in our filings with the Securities and
Exchange Commission, including the risks set forth in our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2016. These forward-looking statements
speak only as of the date hereof. Genomic Health disclaims any
obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Oncotype DX Genomic Prostate Score, Recurrence Score, DCIS Score,
Oncotype SEQ, Oncotype SEQ Liquid Select, and Oncotype IQ are
trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-P
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/comprehensive-economic-analysis-published-in-reviews-in-urology-demonstrates-oncotype-dx-prostate-cancer-test-leads-to-substantial-cost-savings-and-increase-in-active-surveillance-300351246.html
SOURCE Genomic Health, Inc.